French health body favors reimbursement of InterMune lung drug

(Reuters) – InterMune Inc said French health authorities ruled in favor of reimbursing the company’s lung scarring drug Esbriet, potentially covering its costs in a country that is scaling back healthcare spending.


Reuters: Health News